GENSCRIPT BIO Reports Interim Results: Net Loss Narrows 29.25% to $129 Million
Stock News
Aug 16
GENSCRIPT BIO (01548) has released its interim results for the six months ended June 30, 2026, reporting a 27.35% increase in revenue to $404 million. The company's loss attributable to equity holders narrowed by 29.25% to $129 million, with a loss per share of 5.92 cents.
The revenue growth was driven by three key factors. First, rising industry demand for AI-driven drug discovery and antibody drug discovery accelerated the "gene-to-protein" business expansion. Second, a strong recovery in upstream demand within the CRDMO sector boosted project intake and capacity utilization rates. Third, continued expansion in the industrial enzyme business contributed to steady sales growth during the reporting period.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.